Campbell & CO Investment Adviser LLC Purchases 7,001 Shares of Ascendis Pharma A/S $ASND

Key Points

• Campbell & CO Investment Adviser LLC significantly increased its holdings in Ascendis Pharma A/S by 116% in Q1, now owning shares worth $2,032,000.
• Ascendis Pharma reported better-than-expected quarterly earnings, with an EPS of ($0.93) against a consensus estimate of ($1.42), and revenues of $216.28 million surpassing forecasts of $163.17 million.
• Equities analysts have raised price targets for Ascendis Pharma A/S, with Oppenheimer setting a new price objective of $224.00 and maintaining an "outperform" rating.

Campbell & CO Investment Adviser LLC raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 116.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,036 shares of the biotechnology company's stock after purchasing an additional 7,001 shares during the period. Campbell & CO Investment Adviser LLC's holdings in Ascendis Pharma A/S were worth $2,032,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at approximately $28,000. Brooklyn Investment Group increased its stake in shares of Ascendis Pharma A/S by 332.9% during the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 273 shares in the last quarter. Quarry LP bought a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at approximately $96,000. Tower Research Capital LLC TRC increased its stake in shares of Ascendis Pharma A/S by 195.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock valued at $138,000 after purchasing an additional 664 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at approximately $174,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Evercore ISI raised their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Bank of America raised their price target on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the company a "buy" rating in a research report on Monday, June 9th. Oppenheimer reissued an "outperform" rating and set a $224.00 price target (up previously from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Citigroup restated a "buy" rating and issued a $290.00 target price (up previously from $243.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Fifteen analysts have rated the stock with a Buy rating, According to MarketBeat, Ascendis Pharma A/S currently has an average rating of "Buy" and an average target price of $243.36.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock traded up $0.20 on Friday, hitting $194.10. 289,707 shares of the company's stock were exchanged, compared to its average volume of 490,720. The company has a 50-day simple moving average of $179.84 and a 200-day simple moving average of $165.40. The stock has a market capitalization of $11.88 billion, a PE ratio of -37.62 and a beta of 0.41. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $199.99.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.49. The business had revenue of $216.28 million for the quarter, compared to analysts' expectations of $163.17 million. On average, analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.